Loading…
Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease
ACE inhibitors are widely used in treating hypertension and heart failure, but the sites and mechanisms of ACE inhibition in human blood vessels are not understood. The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in diff...
Saved in:
Published in: | Circulation (New York, N.Y.) N.Y.), 1997-07, Vol.96 (1), p.174-182 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 182 |
container_issue | 1 |
container_start_page | 174 |
container_title | Circulation (New York, N.Y.) |
container_volume | 96 |
creator | JIA LONG ZHUO FROOMES, P CASLEY, D LIU, J. J MURONE, C CHAI, S. Y BUXTON, B MENDELSOHN, F. A. O |
description | ACE inhibitors are widely used in treating hypertension and heart failure, but the sites and mechanisms of ACE inhibition in human blood vessels are not understood. The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease.
Sixteen patients with ischemic heart disease were treated either with perindopril (4 mg/d PO) for up to 36 days before surgery (n = 9) or without the inhibitor as control subjects (n = 7). The segments of the internal mammary artery were collected for measurement of vascular free and total ACE by quantitative in vitro autoradiography with 125I-351A binding. The patients treated with perindopril had lower plasma ACE (P < .001) and plasma angiotensin (Ang) II-to-Ang I ratio (P < .05). In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001). Moreover, plasma ACE correlated highly with vascular ACE in the endothelium (r = .85, P < .001) or adventitia (r = .78, P < .001), and mean arterial pressure correlated significantly with free ACE in the endothelium (r = .52, P < .05) or adventitia (r = .53, P < .05) and with the plasma Ang II-to-Ang I ratio (r = .53, P < .05). Light microscopic autoradiographs of 125I-351A binding revealed a marked inhibition of ACE by perindopril in both layers of the vascular wall.
The present demonstrates that long-term administration of perindopril potently inhibits both endothelial and adventitial ACE to a comparable degree in the human internal mammary artery. These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79157037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79157037</sourcerecordid><originalsourceid>FETCH-LOGICAL-p262t-5eade29b7c6f51f8677804d2530c137316bf2b8e799e5d057eb5d947866936a33</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi1U1C4Lj4BkoYpbpMSO7fWxqiggVYIDnCMnnjRTJfbWdlotz8RDMltWPfTk8cw3vz3_vGGbRom2apW0Z2xT17WtjBTigr3L-Z6uWhp1zs6tkLqVYsP-_oSEwcd9wpkPU4oBBzfPB45hwh5L5i7cYSwQMoZqiOERUsFwxyH8OSxAGO9jmXiZgFKeQphxXajLc-cfIRQs6HgcnwkMBVJwM1_csrh04C5R4vgY37uCRGf-hCSHeZhgwYFPQAj3mMFleM_ejm7O8OF0btnvmy-_rr9Vtz--fr--uq32QotSKXAehO3NoEfVjDttzK5uvVCyHhppZKP7UfQ7MNaC8rUy0CtvW7PT2krtpNyyz_919yk-rJBLt9CHYJ5dgLjmzthGmZqUtuzTK_A-rscBcycaQcZrWRP08QSt_QK-I6uPs3enHVD98lR3mbwfkwsD5hdMGEMrVfIfjleUVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212732630</pqid></control><display><type>article</type><title>Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease</title><source>EZB Electronic Journals Library</source><creator>JIA LONG ZHUO ; FROOMES, P ; CASLEY, D ; LIU, J. J ; MURONE, C ; CHAI, S. Y ; BUXTON, B ; MENDELSOHN, F. A. O</creator><creatorcontrib>JIA LONG ZHUO ; FROOMES, P ; CASLEY, D ; LIU, J. J ; MURONE, C ; CHAI, S. Y ; BUXTON, B ; MENDELSOHN, F. A. O</creatorcontrib><description><![CDATA[ACE inhibitors are widely used in treating hypertension and heart failure, but the sites and mechanisms of ACE inhibition in human blood vessels are not understood. The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease.
Sixteen patients with ischemic heart disease were treated either with perindopril (4 mg/d PO) for up to 36 days before surgery (n = 9) or without the inhibitor as control subjects (n = 7). The segments of the internal mammary artery were collected for measurement of vascular free and total ACE by quantitative in vitro autoradiography with 125I-351A binding. The patients treated with perindopril had lower plasma ACE (P < .001) and plasma angiotensin (Ang) II-to-Ang I ratio (P < .05). In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001). Moreover, plasma ACE correlated highly with vascular ACE in the endothelium (r = .85, P < .001) or adventitia (r = .78, P < .001), and mean arterial pressure correlated significantly with free ACE in the endothelium (r = .52, P < .05) or adventitia (r = .53, P < .05) and with the plasma Ang II-to-Ang I ratio (r = .53, P < .05). Light microscopic autoradiographs of 125I-351A binding revealed a marked inhibition of ACE by perindopril in both layers of the vascular wall.
The present demonstrates that long-term administration of perindopril potently inhibits both endothelial and adventitial ACE to a comparable degree in the human internal mammary artery. These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall.]]></description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>PMID: 9236432</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Angiotensin II - blood ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Autoradiography ; Biological and medical sciences ; Cardiovascular system ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - enzymology ; Endothelium, Vascular - pathology ; Hemodynamics - drug effects ; Humans ; In Vitro Techniques ; Indoles - blood ; Indoles - pharmacology ; Indoles - therapeutic use ; Mammary Arteries - drug effects ; Mammary Arteries - enzymology ; Mammary Arteries - pathology ; Medical sciences ; Middle Aged ; Myocardial Ischemia - drug therapy ; Myocardial Ischemia - enzymology ; Myocardial Ischemia - pathology ; Peptidyl-Dipeptidase A - blood ; Perindopril ; Pharmacology. Drug treatments ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Circulation (New York, N.Y.), 1997-07, Vol.96 (1), p.174-182</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jul 1, 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2771525$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9236432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JIA LONG ZHUO</creatorcontrib><creatorcontrib>FROOMES, P</creatorcontrib><creatorcontrib>CASLEY, D</creatorcontrib><creatorcontrib>LIU, J. J</creatorcontrib><creatorcontrib>MURONE, C</creatorcontrib><creatorcontrib>CHAI, S. Y</creatorcontrib><creatorcontrib>BUXTON, B</creatorcontrib><creatorcontrib>MENDELSOHN, F. A. O</creatorcontrib><title>Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description><![CDATA[ACE inhibitors are widely used in treating hypertension and heart failure, but the sites and mechanisms of ACE inhibition in human blood vessels are not understood. The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease.
Sixteen patients with ischemic heart disease were treated either with perindopril (4 mg/d PO) for up to 36 days before surgery (n = 9) or without the inhibitor as control subjects (n = 7). The segments of the internal mammary artery were collected for measurement of vascular free and total ACE by quantitative in vitro autoradiography with 125I-351A binding. The patients treated with perindopril had lower plasma ACE (P < .001) and plasma angiotensin (Ang) II-to-Ang I ratio (P < .05). In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001). Moreover, plasma ACE correlated highly with vascular ACE in the endothelium (r = .85, P < .001) or adventitia (r = .78, P < .001), and mean arterial pressure correlated significantly with free ACE in the endothelium (r = .52, P < .05) or adventitia (r = .53, P < .05) and with the plasma Ang II-to-Ang I ratio (r = .53, P < .05). Light microscopic autoradiographs of 125I-351A binding revealed a marked inhibition of ACE by perindopril in both layers of the vascular wall.
The present demonstrates that long-term administration of perindopril potently inhibits both endothelial and adventitial ACE to a comparable degree in the human internal mammary artery. These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall.]]></description><subject>Aged</subject><subject>Angiotensin II - blood</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Autoradiography</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - enzymology</subject><subject>Endothelium, Vascular - pathology</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Indoles - blood</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Mammary Arteries - drug effects</subject><subject>Mammary Arteries - enzymology</subject><subject>Mammary Arteries - pathology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Ischemia - drug therapy</subject><subject>Myocardial Ischemia - enzymology</subject><subject>Myocardial Ischemia - pathology</subject><subject>Peptidyl-Dipeptidase A - blood</subject><subject>Perindopril</subject><subject>Pharmacology. Drug treatments</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNpdkcFu1DAQhi1U1C4Lj4BkoYpbpMSO7fWxqiggVYIDnCMnnjRTJfbWdlotz8RDMltWPfTk8cw3vz3_vGGbRom2apW0Z2xT17WtjBTigr3L-Z6uWhp1zs6tkLqVYsP-_oSEwcd9wpkPU4oBBzfPB45hwh5L5i7cYSwQMoZqiOERUsFwxyH8OSxAGO9jmXiZgFKeQphxXajLc-cfIRQs6HgcnwkMBVJwM1_csrh04C5R4vgY37uCRGf-hCSHeZhgwYFPQAj3mMFleM_ejm7O8OF0btnvmy-_rr9Vtz--fr--uq32QotSKXAehO3NoEfVjDttzK5uvVCyHhppZKP7UfQ7MNaC8rUy0CtvW7PT2krtpNyyz_919yk-rJBLt9CHYJ5dgLjmzthGmZqUtuzTK_A-rscBcycaQcZrWRP08QSt_QK-I6uPs3enHVD98lR3mbwfkwsD5hdMGEMrVfIfjleUVg</recordid><startdate>19970701</startdate><enddate>19970701</enddate><creator>JIA LONG ZHUO</creator><creator>FROOMES, P</creator><creator>CASLEY, D</creator><creator>LIU, J. J</creator><creator>MURONE, C</creator><creator>CHAI, S. Y</creator><creator>BUXTON, B</creator><creator>MENDELSOHN, F. A. O</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>19970701</creationdate><title>Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease</title><author>JIA LONG ZHUO ; FROOMES, P ; CASLEY, D ; LIU, J. J ; MURONE, C ; CHAI, S. Y ; BUXTON, B ; MENDELSOHN, F. A. O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p262t-5eade29b7c6f51f8677804d2530c137316bf2b8e799e5d057eb5d947866936a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Angiotensin II - blood</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Autoradiography</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - enzymology</topic><topic>Endothelium, Vascular - pathology</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Indoles - blood</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Mammary Arteries - drug effects</topic><topic>Mammary Arteries - enzymology</topic><topic>Mammary Arteries - pathology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Ischemia - drug therapy</topic><topic>Myocardial Ischemia - enzymology</topic><topic>Myocardial Ischemia - pathology</topic><topic>Peptidyl-Dipeptidase A - blood</topic><topic>Perindopril</topic><topic>Pharmacology. Drug treatments</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JIA LONG ZHUO</creatorcontrib><creatorcontrib>FROOMES, P</creatorcontrib><creatorcontrib>CASLEY, D</creatorcontrib><creatorcontrib>LIU, J. J</creatorcontrib><creatorcontrib>MURONE, C</creatorcontrib><creatorcontrib>CHAI, S. Y</creatorcontrib><creatorcontrib>BUXTON, B</creatorcontrib><creatorcontrib>MENDELSOHN, F. A. O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JIA LONG ZHUO</au><au>FROOMES, P</au><au>CASLEY, D</au><au>LIU, J. J</au><au>MURONE, C</au><au>CHAI, S. Y</au><au>BUXTON, B</au><au>MENDELSOHN, F. A. O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1997-07-01</date><risdate>1997</risdate><volume>96</volume><issue>1</issue><spage>174</spage><epage>182</epage><pages>174-182</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract><![CDATA[ACE inhibitors are widely used in treating hypertension and heart failure, but the sites and mechanisms of ACE inhibition in human blood vessels are not understood. The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease.
Sixteen patients with ischemic heart disease were treated either with perindopril (4 mg/d PO) for up to 36 days before surgery (n = 9) or without the inhibitor as control subjects (n = 7). The segments of the internal mammary artery were collected for measurement of vascular free and total ACE by quantitative in vitro autoradiography with 125I-351A binding. The patients treated with perindopril had lower plasma ACE (P < .001) and plasma angiotensin (Ang) II-to-Ang I ratio (P < .05). In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001). Moreover, plasma ACE correlated highly with vascular ACE in the endothelium (r = .85, P < .001) or adventitia (r = .78, P < .001), and mean arterial pressure correlated significantly with free ACE in the endothelium (r = .52, P < .05) or adventitia (r = .53, P < .05) and with the plasma Ang II-to-Ang I ratio (r = .53, P < .05). Light microscopic autoradiographs of 125I-351A binding revealed a marked inhibition of ACE by perindopril in both layers of the vascular wall.
The present demonstrates that long-term administration of perindopril potently inhibits both endothelial and adventitial ACE to a comparable degree in the human internal mammary artery. These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall.]]></abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>9236432</pmid><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 1997-07, Vol.96 (1), p.174-182 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_79157037 |
source | EZB Electronic Journals Library |
subjects | Aged Angiotensin II - blood Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Autoradiography Biological and medical sciences Cardiovascular system Endothelium, Vascular - drug effects Endothelium, Vascular - enzymology Endothelium, Vascular - pathology Hemodynamics - drug effects Humans In Vitro Techniques Indoles - blood Indoles - pharmacology Indoles - therapeutic use Mammary Arteries - drug effects Mammary Arteries - enzymology Mammary Arteries - pathology Medical sciences Middle Aged Myocardial Ischemia - drug therapy Myocardial Ischemia - enzymology Myocardial Ischemia - pathology Peptidyl-Dipeptidase A - blood Perindopril Pharmacology. Drug treatments Vasodilator agents. Cerebral vasodilators |
title | Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perindopril%20chronically%20inhibits%20angiotensin-converting%20enzyme%20in%20both%20the%20endothelium%20and%20adventitia%20of%20the%20internal%20mammary%20artery%20in%20patients%20with%20ischemic%20heart%20disease&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=JIA%20LONG%20ZHUO&rft.date=1997-07-01&rft.volume=96&rft.issue=1&rft.spage=174&rft.epage=182&rft.pages=174-182&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E79157037%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p262t-5eade29b7c6f51f8677804d2530c137316bf2b8e799e5d057eb5d947866936a33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212732630&rft_id=info:pmid/9236432&rfr_iscdi=true |